A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04830644 |
|
Recruitment Status :
Recruiting
First Posted : April 5, 2021
Last Update Posted : July 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Primary Sjögren Syndrome | Drug: Iguratimod Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 144 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome. |
| Actual Study Start Date : | March 22, 2021 |
| Estimated Primary Completion Date : | April 2022 |
| Estimated Study Completion Date : | June 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Iguratimod 1
orally 25mg twice a day
|
Drug: Iguratimod
Iguratimod orally twice a day |
|
Experimental: Iguratimod 2
orally 20mg twice a day
|
Drug: Iguratimod
Iguratimod orally twice a day |
|
Experimental: Iguratimod 3
orally 10mg twice a day
|
Drug: Iguratimod
Iguratimod orally twice a day |
|
Placebo Comparator: Placebo
orally twice a day
|
Drug: Placebo
Placebo orally twice a day |
- Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) [ Time Frame: Week 12 ]
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain.
Overall score, which can range from 0 to 123, a higher score indicates more disease activity
- Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) [ Time Frame: Week 12 ]
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components.
Total Score Range (0 = Best outcome and 10 = Worst Outcome)
The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
- Change From Baseline in the Unstimulated Salivary Flow [ Time Frame: Week 12 ]The mean change from baseline in unstimulated whole salivary flow at all measured time points up to Week 12
- Change From Baseline in Schirmer's Test [ Time Frame: Week 12 ]
The Mean change from baseline in Schirmer's Test at all measured time points up to Week 12
The length in millimeters that the strip wets during the 5 minute test period for each eye. Collection is done separately for each eye.
- Change From Baseline in the level of immunoglobulin (IgG, IgA, IgM) [ Time Frame: Week 12 ]The change from baseline in the level of immunoglobulin (IgG, IgA, IgM) at all measured time points up to Week 12
- Change From Baseline in the level of rheumatoid factor (RF) [ Time Frame: Week 12 ]The change from baseline in the level of RF at all measured time points up to Week 12
- Change From Baseline in the level of B -cell activation factor (BAFF) [ Time Frame: Week 12 ]The change from baseline in the level of BAFF at all measured time points up to Week 12
- Change From Baseline in the level of T/B/NK cell subsets [ Time Frame: Week 12 ]The change from baseline in the level of T/B/NK cell subsets at all measured time points up to Week 12
- Change From Baseline in the level of erythrocyte sedimentation rate (ESR) [ Time Frame: Week 12 ]The change from baseline in the level of ESR at all measured time points up to Week 12
- Change From Baseline in the level of serum complement (C3 and C4) [ Time Frame: Week 12 ]The change from baseline in the level of serum complement (C3 and C4) at all measured time points up to Week 12
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- meet the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism Classification Criteria for Sjogren's Syndrome (EULAR SS)
- ESSDAI score ≥6
- IgG >16 g/L
- Positive anti-SS-A/Ro antibody at screening
Exclusion Criteria:
- Pregnancy or breast feeding
- Secondary Sjogren's syndrome
- severe renal or haematological failure, a history of cancer, hepatitis B or C, human immunodeficiency virus, severe diabetes or any other chronic disease or evidence of infection
-
Prior administration of any of the following:
- Rituximab in the past 12 months prior to randomization;
- Cyclophosphamide, mycophenolate mofetil, methotrexate, leflunomide and iguratimod in the past 12 weeks prior to randomization;
- Azathioprine, cyclosporin, tacrolimus, sirolimus, sulfasalazine in the past 4 weeks prior to randomization;
- live vaccine in the past 12 weeks prior to randomization
- Corticosteroids: > 10 mg/day oral prednisone (or equivalent); Any change or initiation of new dose within 4 weeks prior to randomization; Intramuscular, subcutaneous, intravenous, or intra-articular corticosteroids within 4 weeks prior to randomization.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04830644
| Contact: Lai Zhiqiang | +86-18697190725 | laizhiqiang@simcere.com |
Show 30 study locations
| Responsible Party: | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT04830644 |
| Other Study ID Numbers: |
SIM 1910-08-Ⅱ |
| First Posted: | April 5, 2021 Key Record Dates |
| Last Update Posted: | July 19, 2021 |
| Last Verified: | July 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Sjogren's Syndrome Syndrome Disease Pathologic Processes Arthritis, Rheumatoid Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Xerostomia |
Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Dry Eye Syndromes Lacrimal Apparatus Diseases Eye Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |